Clinical Trials
6 trialsNCT04214249 2026-05-28
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01350245 2025-05-16
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Thomas Jefferson University
Phase 2 Completed
NCT02484391 2024-09-19
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT00568633 2019-09-24
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
Phase 3 Terminated
NCT00589563 2014-09-10
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Phase 2 Completed